B7-H3 CAR T Cell Locoregional Immunotherapy Trial
Phase 1
90
about 21 years
1–26
1 site in WA
What this study is about
Researchers are testing a new treatment called B7-H3 CAR T cell locoregional immunotherapy for certain types of brain tumors. This treatment involves using specially engineered immune cells to target and destroy cancer cells in the brain. The trial will involve children and young adults with specific brain tumors, including DIPG and DMG.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy
Primary: Establish the safety, defined by the adverse events, of B7H3-specific CAR T cell infusions delivered by a central nervous system (CNS) catheter into the tumor resection cavity or ventricular system
Oncology